Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Autor: Abu-Rustum NR; Memorial Sloan Kettering Cancer Center., Yashar CM; UC San Diego Moores Cancer Center., Arend R; O'Neal Comprehensive Cancer Center at UAB., Barber E; Robert H. Lurie Comprehensive Cancer Center of Northwestern University., Bradley K; University of Wisconsin Carbone Cancer Center., Brooks R; UC Davis Comprehensive Cancer Center., Campos SM; Dana-Farber/Brigham and Women's Cancer Center., Chino J; Duke Cancer Institute., Chon HS; Moffitt Cancer Center., Crispens MA; Vanderbilt-Ingram Cancer Center., Damast S; Yale Cancer Center/Smilow Cancer Hospital., Fisher CM; University of Colorado Cancer Center., Frederick P; Roswell Park Comprehensive Cancer Center., Gaffney DK; Huntsman Cancer Institute at the University of Utah., Gaillard S; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins., Giuntoli R II; Abramson Cancer Center at the University of Pennsylvania., Glaser S; City of Hope National Medical Center., Holmes J; Indiana University Melvin and Bren Simon Comprehensive Cancer Center., Howitt BE; Stanford Cancer Institute., Kendra K; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., Lea J; UT Southwestern Simmons Comprehensive Cancer Center., Lee N; The UChicago Medicine Comprehensive Cancer Center., Mantia-Smaldone G; Fox Chase Cancer Center., Mariani A; Mayo Clinic Comprehensive Cancer Center., Mutch D; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine., Nagel C; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., Nekhlyudov L; Dana-Farber/Brigham and Women's Cancer Center., Podoll M; Vanderbilt-Ingram Cancer Center., Rodabaugh K; Fred & Pamela Buffett Cancer Center., Salani R; UCLA Jonsson Comprehensive Cancer Center., Schorge J; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center., Siedel J; University of Michigan Rogel Cancer Center., Sisodia R; Mass General Cancer Center., Soliman P; The University of Texas MD Anderson Cancer Center., Ueda S; UCSF Helen Diller Family Comprehensive Cancer Center., Urban R; Fred Hutchinson Cancer Center., Wethington SL; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins., Wyse E; Patient Advocate., Zanotti K; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute., McMillian N; National Comprehensive Cancer Network., Espinosa S; National Comprehensive Cancer Network.

Publikováno v: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2024 Mar; Vol. 22 (2), pp. 117-135.

Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.

Autor: Ackroyd SA; Fox Chase Cancer Center, Department of Gynecologic Oncology, 333 Cottman Avenue, Philadelphia, PA 19111, USA; University of Chicago Medicine, 5941 S Maryland Ave., Chicago, IL 60637, USA., Arguello D; Caris Life Science, 4610 S. 44(th) Place Phoenix, AZ 85040, USA., Ramos P; Caris Life Science, 4610 S. 44(th) Place Phoenix, AZ 85040, USA., Mahdi H; Cleveland Clinic, Desk A81, 9500 Euclid Ave., Cleveland, OH 44195, USA., ElNaggar A; West Cancer Center and Research Institute, 7945 Wolf River Blvd., Germantown, TN 38138, USA., Winer I; Karmanos Cancer Institute, Wayne State University, 4100 John R St., Detroit, MI 48201, USA., Holloway R; Florida Hospital Cancer Institute, 2501 N. Orange Ave., Orlando, FL 32804, USA., Krivak T; Allegheny Health Network, Pittsburg, PA, USA., Jones N; Mitchell Cancer Institute, USA Mitchell Cancer Institute, 1660 Spring Hill Ave., Mobile, AL 36604, USA., Turner VG; University of Texas at Austin Dell Medical School, Department of Women's Health, 1601 Trinity St. Bldg. A, Austin, TX 78712, USA., Herzog T; University of Cincinnati Cancer Institute, Gynecologic Oncology Center, 234 Goodman St., Cincinnati, OH 45219, USA., Chu C; Fox Chase Cancer Center, Department of Gynecologic Oncology, 333 Cottman Avenue, Philadelphia, PA 19111, USA., Brown J; Levine Cancer Institute-Morehead, 1021 Morehead Medical Drive, Charlotte, NC 28204, USA., Mantia-Smaldone G; Fox Chase Cancer Center, Department of Gynecologic Oncology, 333 Cottman Avenue, Philadelphia, PA 19111, USA. Electronic address: Gina.Mantia-Smaldone@fccc.edu.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2023 Feb; Vol. 169, pp. 164-171. Date of Electronic Publication: 2022 Nov 01.

833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer

Autor: O'Malley, D.M., Richardson, D.L., Vergote, I.B., Gilbert, L., Castro, C., Provencher, D., Matulonis, U.A., Mantia-Smaldone, G., Martin, L., Zweidler-Mckay, P.A., Moore, K.N.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S626-S627

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors.

Autor: Venkatachalam, Annapoorna^1,2 (AUTHOR), Correia, Cristina² (AUTHOR), Peterson, Kevin L.² (AUTHOR), Hou, Xianon² (AUTHOR), Schneider, Paula A.² (AUTHOR), Strathman, Annabella R.² (AUTHOR), Flatten, Karen S.² (AUTHOR), Sine, Chance C.² (AUTHOR), Balczewski, Emily A.^2,3 (AUTHOR), McGehee, Cordelia D.¹ (AUTHOR), Larson, Melissa C.⁴ (AUTHOR), Duffield, Laura N.² (AUTHOR), Meng, X. Wei² (AUTHOR), Vincelette, Nicole D.^1,5 (AUTHOR), Ding, Husheng² (AUTHOR), Oberg, Ann L.⁶ (AUTHOR), Couch, Fergus J.⁷ (AUTHOR), Swisher, Elizabeth M.⁸ (AUTHOR), Li, Hu¹ (AUTHOR), Weroha, S. John^1,2 (AUTHOR)

Publikováno v: Molecular Cancer. 10/7/2024, Vol. 23 Issue 1, p1-16. 16p.

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Autor: Lheureux S; Princess Margaret Cancer Centre, Toronto, ON, Canada., Cristea MC; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Bruce JP; Princess Margaret Cancer Centre, Toronto, ON, Canada., Garg S; Princess Margaret Cancer Centre, Toronto, ON, Canada., Cabanero M; Princess Margaret Cancer Centre, Toronto, ON, Canada., Mantia-Smaldone G; Fox Chase Cancer Center, Philadelphia, PA, USA., Olawaiye AB; UPMC Mercy, Pittsburgh, PA, USA., Ellard SL; BC Cancer Kelowna, Kelowna, BC, Canada., Weberpals JI; Ottawa Regional Cancer Center, Ottawa, ON, Canada., Wahner Hendrickson AE; Mayo Clinic Cancer Center, Rochester, MN, USA., Fleming GF; University of Chicago, Chicago, IL, USA., Welch S; London Regional Cancer Program, London, ON, Canada., Dhani NC; Princess Margaret Cancer Centre, Toronto, ON, Canada., Stockley T; Princess Margaret Cancer Centre, Toronto, ON, Canada., Rath P; Ontario Institute for Cancer Research, Toronto, ON, Canada., Karakasis K; Princess Margaret Cancer Centre, Toronto, ON, Canada., Jones GN; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK., Jenkins S; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK., Rodriguez-Canales J; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK., Tracy M; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK., Tan Q; Princess Margaret Cancer Centre, Toronto, ON, Canada., Bowering V; Princess Margaret Cancer Centre, Toronto, ON, Canada., Udagani S; Princess Margaret Cancer Centre, Toronto, ON, Canada., Wang L; Princess Margaret Cancer Centre, Toronto, ON, Canada., Kunos CA; National Cancer Institute, Bethesda, MA, USA., Chen E; Princess Margaret Cancer Centre, Toronto, ON, Canada., Pugh TJ; Princess Margaret Cancer Centre, Toronto, ON, Canada., Oza AM; Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: amit.oza@uhn.ca.

Publikováno v: Lancet (London, England) [Lancet] 2021 Jan 23; Vol. 397 (10271), pp. 281-292.